{"id":39093,"date":"2025-08-12T14:35:46","date_gmt":"2025-08-12T06:35:46","guid":{"rendered":"https:\/\/flcube.com\/?p=39093"},"modified":"2025-08-12T14:35:47","modified_gmt":"2025-08-12T06:35:47","slug":"hengruis-trastuzumab-rezetecan-and-adebrelimab-granted-breakthrough-therapy-designation-by-chinas-nmpa","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=39093","title":{"rendered":"Hengrui&#8217;s Trastuzumab Rezetecan and Adebrelimab Granted Breakthrough Therapy Designation by China&#8217;s NMPA"},"content":{"rendered":"\n<p>China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/1276:HKG\">HKG: 1276<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/600276:SHA\">SHA: 600276<\/a>) announced on August 11, 2025, that its innovative drugs, trastuzumab rezetecan injection and adebrelimab injection, have been granted breakthrough therapy designation by China&#8217;s National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE). The designation covers the combination of trastuzumab rezetecan and adebrelimab for first-line treatment of PD-L1-positive (CPS\u22651), locally recurrent, unresectable, or metastatic triple-negative breast cancer. This marks the ninth indication for trastuzumab rezetecan on the breakthrough therapy list.<\/p>\n\n\n\n<p><strong>Drug Mechanisms<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Trastuzumab Rezetecan<\/strong>: This HER2-targeted antibody-drug conjugate (ADC) binds to HER2-expressing tumor cells and releases a cytotoxic payload, inducing cell cycle arrest and apoptosis. It received marketing approval in May 2025 for treating HER2-mutated non-small cell lung cancer (NSCLC) patients in China.<\/li>\n\n\n\n<li><strong>Adebrelimab<\/strong>: A humanized anti-PD-L1 monoclonal antibody that reactivates the immune system&#8217;s anti-tumor activity by blocking the PD-1\/PD-L1 pathway. It was launched in March 2023 for extensive-stage small cell lung cancer treatment.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced on August 11, 2025,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":39095,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,34,16,29,2586,4228,852],"class_list":["post-39093","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-adc-xdc","tag-breakthrough-therapy","tag-cancer","tag-combination-therapy","tag-hengrui-pharmaceuticals","tag-hkg-1276","tag-sha-600276"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hengrui&#039;s Trastuzumab Rezetecan and Adebrelimab Granted Breakthrough Therapy Designation by China&#039;s NMPA - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced on August 11, 2025, that its innovative drugs, trastuzumab rezetecan injection and adebrelimab injection, have been granted breakthrough therapy designation by China&#039;s National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE). The designation covers the combination of trastuzumab rezetecan and adebrelimab for first-line treatment of PD-L1-positive (CPS\u22651), locally recurrent, unresectable, or metastatic triple-negative breast cancer. This marks the ninth indication for trastuzumab rezetecan on the breakthrough therapy list.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=39093\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hengrui&#039;s Trastuzumab Rezetecan and Adebrelimab Granted Breakthrough Therapy Designation by China&#039;s NMPA\" \/>\n<meta property=\"og:description\" content=\"China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced on August 11, 2025, that its innovative drugs, trastuzumab rezetecan injection and adebrelimab injection, have been granted breakthrough therapy designation by China&#039;s National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE). The designation covers the combination of trastuzumab rezetecan and adebrelimab for first-line treatment of PD-L1-positive (CPS\u22651), locally recurrent, unresectable, or metastatic triple-negative breast cancer. This marks the ninth indication for trastuzumab rezetecan on the breakthrough therapy list.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=39093\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-12T06:35:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-12T06:35:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1211.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39093#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39093\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hengrui&#8217;s Trastuzumab Rezetecan and Adebrelimab Granted Breakthrough Therapy Designation by China&#8217;s NMPA\",\"datePublished\":\"2025-08-12T06:35:46+00:00\",\"dateModified\":\"2025-08-12T06:35:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39093\"},\"wordCount\":173,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39093#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1211.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"Breakthrough therapy\",\"Cancer\",\"Combination therapy\",\"Hengrui Pharmaceuticals\",\"HKG: 1276\",\"SHA: 600276\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=39093#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39093\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=39093\",\"name\":\"Hengrui's Trastuzumab Rezetecan and Adebrelimab Granted Breakthrough Therapy Designation by China's NMPA - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39093#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39093#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1211.webp\",\"datePublished\":\"2025-08-12T06:35:46+00:00\",\"dateModified\":\"2025-08-12T06:35:47+00:00\",\"description\":\"China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced on August 11, 2025, that its innovative drugs, trastuzumab rezetecan injection and adebrelimab injection, have been granted breakthrough therapy designation by China's National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE). The designation covers the combination of trastuzumab rezetecan and adebrelimab for first-line treatment of PD-L1-positive (CPS\u22651), locally recurrent, unresectable, or metastatic triple-negative breast cancer. This marks the ninth indication for trastuzumab rezetecan on the breakthrough therapy list.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39093#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=39093\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39093#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1211.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1211.webp\",\"width\":1080,\"height\":608,\"caption\":\"Hengrui's Trastuzumab Rezetecan and Adebrelimab Granted Breakthrough Therapy Designation by China's NMPA\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39093#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hengrui&#8217;s Trastuzumab Rezetecan and Adebrelimab Granted Breakthrough Therapy Designation by China&#8217;s NMPA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hengrui's Trastuzumab Rezetecan and Adebrelimab Granted Breakthrough Therapy Designation by China's NMPA - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced on August 11, 2025, that its innovative drugs, trastuzumab rezetecan injection and adebrelimab injection, have been granted breakthrough therapy designation by China's National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE). The designation covers the combination of trastuzumab rezetecan and adebrelimab for first-line treatment of PD-L1-positive (CPS\u22651), locally recurrent, unresectable, or metastatic triple-negative breast cancer. This marks the ninth indication for trastuzumab rezetecan on the breakthrough therapy list.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=39093","og_locale":"en_US","og_type":"article","og_title":"Hengrui's Trastuzumab Rezetecan and Adebrelimab Granted Breakthrough Therapy Designation by China's NMPA","og_description":"China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced on August 11, 2025, that its innovative drugs, trastuzumab rezetecan injection and adebrelimab injection, have been granted breakthrough therapy designation by China's National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE). The designation covers the combination of trastuzumab rezetecan and adebrelimab for first-line treatment of PD-L1-positive (CPS\u22651), locally recurrent, unresectable, or metastatic triple-negative breast cancer. This marks the ninth indication for trastuzumab rezetecan on the breakthrough therapy list.","og_url":"https:\/\/flcube.com\/?p=39093","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-12T06:35:46+00:00","article_modified_time":"2025-08-12T06:35:47+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1211.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=39093#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=39093"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hengrui&#8217;s Trastuzumab Rezetecan and Adebrelimab Granted Breakthrough Therapy Designation by China&#8217;s NMPA","datePublished":"2025-08-12T06:35:46+00:00","dateModified":"2025-08-12T06:35:47+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=39093"},"wordCount":173,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=39093#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1211.webp","keywords":["ADC \/ XDC","Breakthrough therapy","Cancer","Combination therapy","Hengrui Pharmaceuticals","HKG: 1276","SHA: 600276"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=39093#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=39093","url":"https:\/\/flcube.com\/?p=39093","name":"Hengrui's Trastuzumab Rezetecan and Adebrelimab Granted Breakthrough Therapy Designation by China's NMPA - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=39093#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=39093#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1211.webp","datePublished":"2025-08-12T06:35:46+00:00","dateModified":"2025-08-12T06:35:47+00:00","description":"China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced on August 11, 2025, that its innovative drugs, trastuzumab rezetecan injection and adebrelimab injection, have been granted breakthrough therapy designation by China's National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE). The designation covers the combination of trastuzumab rezetecan and adebrelimab for first-line treatment of PD-L1-positive (CPS\u22651), locally recurrent, unresectable, or metastatic triple-negative breast cancer. This marks the ninth indication for trastuzumab rezetecan on the breakthrough therapy list.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=39093#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=39093"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=39093#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1211.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1211.webp","width":1080,"height":608,"caption":"Hengrui's Trastuzumab Rezetecan and Adebrelimab Granted Breakthrough Therapy Designation by China's NMPA"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=39093#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hengrui&#8217;s Trastuzumab Rezetecan and Adebrelimab Granted Breakthrough Therapy Designation by China&#8217;s NMPA"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1211.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39093","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=39093"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39093\/revisions"}],"predecessor-version":[{"id":39096,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39093\/revisions\/39096"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/39095"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=39093"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=39093"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=39093"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}